FOLH1 and prostate carcinoma: It is comprised of PSMA-617, a small molecule designed to bind with high affinity to PSMA and that target prostate cancer cells [7], the Glu-urea-Lys PSMA binding motif, and the DOTA/DOTAGA chelator linked with lutetium-177, which releases energetic beta particles that destroy cancer cells at the disease site [8,9].